Figure 2.

(A) 3-month exacerbation rates in patients with moderate, severe, and very severe COPD receiving B/F or placebo; and (B) 3-month exacerbation rate ratios between B/F and placebo, by disease severity. Vertical lines represent 95% confidence intervals. Moderate COPD was defined as post-bronchodilator FEV₁ 80%–50% predicted, severe COPD as post-bronchodilator FEV₁ 50%–30% predicted, and very severe COPD as post-bronchodilator FEV₁ <30% predicted, according to GOLD 2016 criteria (3-month data set; Calverley et al, Szafranski et al, and CLIMB studies).⁹,¹⁰,¹²

Abbreviations: B/F, budesonide/formoterol; COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 s.